Transparency Reporting has increased in its reach and complexity manifold in the last decade. The journey has been rapid and challenging, from limited states in US mandating HCP transparency reporting in 2010, to expansive regulations, industry directives, laws and more across five continents and over 70 countries requiring drug and device manufacturers to report transparency payments.

Is there a best practice blueprint? We believe there is! Sometimes referred to as Global Transparency 2.0. Come join us as big pharma and industry practice leaders pair up to share specific capabilities to help global compliance teams to get to Global transparency 2.0.

Why should you attend this Webinar?

• Legal Insights
• Pre-Disclosure.
• Reporting Regulations.
• Best practices for manufacturers to ensure accurate Payment Tracking and Reporting amidst recent law changes.
• Use of Analytics and Monitoring to understand and safeguard Spend.

Melissa Lafrain, Director of Astra Zeneca, and Dr. Klaus Geldsetzer Former CCO Santen Pharmaceuticals – Germany are pairing up to share deep knowledge and experience of the global transparency reporting, evolving industry trends, and guidance on best practices and will share valuable guidance on ways to transition from basic reporting methods to monitoring, certification, disclosure, analytics, digital signatures, auditing & more referred to as Global Transparency 2.0

This Webinar is best for?